Roth/MKM maintained a positive stance on Canopy Growth (NASDAQ:CGC) shares, despite reducing the price target to C$10 from the previous C$15. The firm continues to endorse a Buy rating for the ...

Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Canopy Growth (TSE:WEED – Get Free Report) had its target price lowered by equities research analysts at ATB Capital from C$4.00 to C$3.20 in a research note issued on Monday,BayStreet.CA reports. The ...

Canopy Growth (TSE:WEED – Get Free Report) had its target price decreased by analysts at Canaccord Genuity Group from C$2.50 to C$1.50 in a research report issued to clients and investors on ...

北京时间2025年02月01日02时59分，Canopy Growth Corporation（CGC.us）股票出现波动，股价快速下挫5.24%。截至发稿，该股报1.99美元/股，成交量313.1万股， 换手率 2.56%，振幅6.19%。

Canopy Growth Corporation股票所在的制药行业中，整体涨幅为0.91%。其相关个股中，Quantum Biopharma Ltd.、坎伯兰药业、Incannex Healthcare Inc.涨幅较大，Quantum Biopharma Ltd.、坎伯兰药业、大自然药业较为活跃，换手率分别为3178.15%、82.10%、18.45%，振幅较大的相关个股有Quantum ...

Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Canopy Growth (CGC) to C$4 from C$7 and keeps a Neutral rating ...

Canopy Growth (CGC)发布Q3财报，2025财年前三财季累计收入2.04亿加拿大元，去年同期累计收入为2.24亿加拿大元，同比减少9.09%。 Canopy Growth Corporation于2014年4月在加拿大成立，成为北美第一家公开交易的大麻公司。

Canopy Growth Corporation ("Canopy Growth" or the ... political delays and market volatility have affected cannabis stock. "We keep expecting federal reform, we keep getting promised federal ...

I last wrote about it after they reported their fiscal Q2 in November, suggesting that investors should avoid Canopy Growth. I suggested that the stock, then above $4, could drop to $1.